Quantcast FDA Approvals FDA Approvals

​FDA Approvals

 

 

A New Molecularly Targeted Therapeutic for Breast Cancer5126The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of the disease.10/17/2017 7:46:40 PM306https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1710006A_BreastCancer_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Molecularly Targeted Therapeutic for Breast CancerThe FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of the disease.55
Expanding the Use of an Immunotherapeutic to Liver Cancer5078The FDA decision means the immune checkpoint inhibitor nivolumab is now approved for eight types of cancer.10/13/2017 2:12:51 PM154https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1710004A_Nivolumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding the Use of an Immunotherapeutic to Liver CancerThe FDA decision means the immune checkpoint inhibitor nivolumab is now approved for eight types of cancer.54
Immunotherapy for Stomach Cancer4582The FDA has approved pembrolizumab for treating certain patients with advanced stomach (gastric) cancer.10/12/2017 1:31:04 PM302https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1710005A_Stomach_150x190_1.jpg" style="BORDER&#58;0px solid;" />Immunotherapy for Stomach CancerThe FDA has approved pembrolizumab for treating certain patients with advanced stomach (gastric) cancer.53
Targeting Non-Hodgkin Lymphoma525A new molecularly targeted therapeutic to treat certain patients with follicular lymphoma, a common type of non-Hodgkin lymphoma, has been approved.10/10/2017 8:18:50 PM244https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709114A_Targeting_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Non-Hodgkin LymphomaA new molecularly targeted therapeutic to treat certain patients with follicular lymphoma, a common type of non-Hodgkin lymphoma, has been approved.52
Groundbreaking New Immunotherapy Approved for Acute Lymphoblastic Leukemia (ALL)20893The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T–cell therapy for ALL.9/8/2017 6:32:58 PM1634https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709009_Tcelltherapy_150x190_1.jpg" style="BORDER&#58;0px solid;" />Groundbreaking New Immunotherapy Approved for Acute Lymphoblastic Leukemia (ALL)The U.S. Food and Drug Administration has approved the first of a new type of immunotherapy called CAR T–cell therapy for ALL.47
Targeting Adult Acute Lymphoblastic Leukemia25404The FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL.9/19/2017 3:20:47 PM471https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709008_Ozogamicin_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Adult Acute Lymphoblastic LeukemiaThe FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL.51
FDA Approves a New Treatment for Acute Myeloid Leukemia20921The new treatment, Vyxeos, comprises a combination of two commonly used cytotoxic chemotherapeutics inside a nanosized particle.9/14/2017 7:54:37 PM335https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709011_Vyzeos_150x190_1.jpg" style="BORDER&#58;0px solid;" />FDA Approves a New Treatment for Acute Myeloid LeukemiaThe new treatment, Vyxeos, comprises a combination of two commonly used cytotoxic chemotherapeutics inside a nanosized particle.50
Targeting Acute Myeloid Leukemia20873Enasidenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months.9/12/2017 4:36:17 PM378https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709010_Enasidenib_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Acute Myeloid LeukemiaEnsadenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months. 49
Expanding the Use of an Immunotherapeutic to Colorectal Cancer20886The FDA decision means the immune checkpoint inhibitor nivolumab is now approved for seven types of cancer.9/8/2017 7:03:45 PM91https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1709007_Nivolumab_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding the Use of an Immunotherapeutic to Colorectal CancerThe FDA decision means the immune checkpoint inhibitor nivolumab is now approved for seven types of cancer. 48
Targeting HER2-positive Breast Cancer20915The FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer.7/24/2017 7:28:56 PM122https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1707042_HER2pos_Headshot_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting HER2-positive Breast CancerThe FDA has approved a new HER2-targeted therapeutic for the treatment of certain patients with early-stage breast cancer.46

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300